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Abstract
Heparin-induced thrombocytopenia type II (HIT II) is a rare immune-mediated complication of
heparin. The diagnosis of HIT is considered in patients exposed to heparin, presenting with
thrombocytopenia and thrombosis.
We present two cases with massive pulmonary embolism and HIT, successfully treated with the
administration of fondaparinux, an alternative anticoagulant, combined with the insertion of an
inferior vena cava filter for the prevention of new thromboembolic events. The two cases
supplement the available data of the use of fondaparinux in patients with HIT and pulmonary
embolism, before further large studies establish its efficacy and safety in this group of patients.
Moreover, the management of these patients reveals the need for future evaluation of the
combined therapy of alternative anticoagulant agents with the placement of vena cava filters.
Background
Heparin in its two forms (unfractionated heparin and
low-molecular weight heparin) remains the mainstay of
treatment for venous and arterial thromboembolism.
Heparin-induced thrombocytopenia type II (HIT II) is a
well documented, immune mediated severe adverse effect
of heparin, caused by IgG (more rarely IgM) antibodies
against the heparin/platelet factor 4 (PF4) complex,
resulting in platelet activation and aggregation, endothe-
lian activation, thrombin generation and eventually in
thrombocytopenia and thrombotic events [1,2]. For
patients with HIT II, the discontinuation of heparin alone
is not sufficient and the diagnosis necessitates the admin-
istration of an alternative anticoagulant [3-5].
We report the cases of two patients with HIT II and mas-
sive pulmonary embolism, successfully managed with
fondaparinux sodium, a novel selective inhibitor of acti-
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vated factor X and the insertion of an inferior vena cava fil-
ter.
Cases presentation
The first case involved a 60-year-old woman with intracra-
nial hemorrhage, hospitalized in our hospital in a stable
neurological state. She had a history of a total arthroplasty
of her right ischium 25 days ago and mild thrombocyto-
penia after the administration of low molecular weight
heparin, which had been replaced by aspirin. On day 5,
she developed acute respiratory failure with clinical signs
of right heart failure, due to massive pulmonary embo-
lism and deep venous thrombosis at the level of right iliac,
femoral and popliteal veins. At that time, the platelet
count was determined at 50.000/μL, disseminated intra-
vascular coagulation was not present and all routine labo-
ratory tests were within normal limits.
In view of thrombocytopenia after the administration of
low molecular weight heparin and the thromboembolic
events, HIT was clinically suspected. The diagnosis was
confirmed three days later, by the positive enzyme immu-
noassay for antibodies to heparin-platelet factor 4 (Asser-
achrom HPIA, Diagnostica Stago). Antibody titers were
determined on citrated plasma and results were expressed
as percent of the absorbance measured at 450 nm with a
positive control (1.900 optical density units), represent-
ing the value 100%. Antibody titers were estimated to be
87% (cut off for positive value 23%).
Despite the increased risk of a recurrent intracranial hem-
orrhage, the presence of severe deep venous thrombosis
on the ground of HIT immediated the administration of
an alternative anticoagulant and fondaparinux sodium
(Arixtra®, GlaxoSmithKline) was started subcutaneously
in the dose of 7,5 mg daily. Given the severity of the
patient's condition and her stabilized neurological status,
we decided the administration of the highest recom-
mended dose. Furthermore, the insertion of vena cava fil-
ter (Gunther, Tulip™, Cook USA) was decided for the
prevention of new embolic events. The clinical status of
the patients gradually improved and platelet count nor-
malized 5 days after the initiation of fondaparinux (figure
1). No further bleeding or new thrombosis were observed.
The patient was discharged on fondaparinux treatment
after 16 days of hospitalization.
The second case was a 32-year-old man, with a medical
history of thrombophilia due to hyperhomocystinaemia,
hospitalized in our department with massive pulmonary
embolism and deep venous thrombosis of his lower
extremities, in both popliteal veins. Due to cardiovascular
instability and severe respiratory failure, the patient
underwent thrombolysis with recombinant tissue plas-
minogen activator at the dose of 100 mg in 2 hours intra-
venously (Actilyse®, Boehringer) and an inferior vena cava
filter (Gunther Tulip™, Cook USA) was inserted. Subse-
quently, he was given intravenously unfractionated
heparin (UFH), accordingly to Rascke protocol (80 U/kg
bolus followed by 18 U/kgr/h). At that time the platelet
count was determined at 239.000/ml. On day 6, the
patient manifested clinical evidence of right lower extrem-
ity deep venous thrombosis and in parallel, a decrease in
his platelet count to 110.000/μL. The spiral computed
tomography of the lower extremities vessels showed new
thrombi extending in both iliac and femoral veins up to
the level of inferior vena cava filter.
The heparin/PF4 enzyme-linked immunosorbent assay
(ELISA) for platelet depended antibodies was strongly
positive (65%), confirming the diagnosis of HIT on day 9.
Fondaparinux sodium was administrated subcutaneously
at the dose of 7,5 mg daily. No further thromboembolic
episodes occurred and the platelet count increased stead-
ily three days later (figure 1). The patient was discharged
after 14 days of hospitalization, on long-term treatment
with fondaparinux.
Discussion
Heparin induced thrombocytopenia is a rare and serious
adverse drug reaction, accompanied with a mortality rate
from 18.8 to 50% without treatment [5-7]. In most cases,
no other cause for platelet count fall is evident and despite
thrombocytopenia, patients manifest new or recurrent
venous and/or arterial thrombosis. A retrospective analy-
sis showed that 40–61% of patients with HIT developed
thrombosis after the cessation of heparin alone [8]. It is of
note that venous thromboembolism (VTE) is infrequently
associated with HIT in LMWH treated patients (<1%) [9].
Regarding the therapeutic management of HIT, the cur-
rently available alternative anticoagulants are lepirudin,
argatroban and danaparoid. Among these agents, lepiru-
din and argatroban are the treatments approved by the
FDA for managing HIT and only lepirudin is available in
Greece. However, lepirudin requires monitoring, as the
risk of major hemorrhage is directly related to APTT ratio
and renal function [10].
Fondaparinux sodium is a new synthetic analogue of the
binding site within heparin specific for antithrombin III.
Its pharmacokinetic properties allow for a simple once-
daily regimen, in a dose between 2.5 and 7.5 mg subcuta-
neously, without monitoring [7]. Many case reports and
retrospective reviews showed encouraging results favour-
ing its use in the therapy of HIT [11]. However, two recent
case reports of fondaparinux-related thrompocytopenia
and thrombosis [12] and fondaparinux-associated throm-
bocytopenia in a previous LMWH-HIT [13] respectively
highlight the fact that its safety need to be further clarified.Thrombosis Journal 2008, 6:9 http://www.thrombosisjournal.com/content/6/1/9
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A previous study showed that fondaparinux does not acti-
vate platelets in the presence of sera obtained from
patients with HIT with a statistically significant difference
comparing to UFH[14], and recently, Warkentin et al[15]
showed that the frequency of formation of anti-PF4/
heparin antibodies was the same for orthopedic surgery
patients receiving fondaparinux or enoxaparin but the risk
of developing HIT was very low.
In hemodynamically stable patients with acute sympto-
matic pulmonary embolism, once-daily subcutaneously
fondaparinux appears to be at least as effective and safe as
unfractionated heparin for the initial treatment of pulmo-
nary embolism [16] and in patients with acute sympto-
matic deep venous thrombosis, fondaparinux was at least
as effective and safe as twice-daily body-weight adjusted
enoxaparin for their initial treatment [17].
Taking into account the published data and its properties,
fondaparinux provided to us a logical alternative antico-
agulant for our patients who suffered from HIT, massive
pulmonary embolism and deep venous thrombosis.
To our knowledge, there are limited data in the literature
for invasive approaches to the treatment of HIT. Emig et al
reported the case of a woman with massive thrombosis of
The course of platelet count of both patients during hospitalization in association with clinical events and laboratory confirma- tion of HIT Figure 1
The course of platelet count of both patients during hospitalization in association with clinical events and laboratory confirma-
tion of HIT. Laboratory tests results at the time of the diagnosis, included increased fibrin d-dimer levels (>20 μg/ml and 4.1 
μg/ml respectively; normal value <0.5 μg per milliliter) and indicated the absence of disseminated intravascular coagulation 
(International Normalized Ratio 1.1 and 1.0, respectively; normal range 0.9 to 1.2) without circulating nucleated red cells.Thrombosis Journal 2008, 6:9 http://www.thrombosisjournal.com/content/6/1/9
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the iliofemoral and caval veins in the HIT syndrome [18],
who was successfully managed with the combination of
transcatheter administration of urokinase and systemic
infusion of danaparoid, under the protection of a tempo-
ral vena cava filter.
Our first patient developed deep venous thrombosis and
massive pulmonary embolism, as a result of HIT syn-
drome. Given the fact that a recurrent embolic event
might have been fatal, the patient required prompt and
aggressive management with combined therapy with an
alternative anticoagulant and the placement of an inferior
vena cava filter. In the second case, the initial treatment of
massive pulmonary embolism was thrombolysis, fol-
lowed by the administration of UFH and the insertion of
an inferior vena cava filter. The recurrent deep venous
thrombosis up to the level of the IVC filter was the result
of the HIT syndrome, which was managed by the admin-
istration of fondaparinux. It is thus considered that the
cava filter had been proved life saving and prevented new,
probably fatal, pulmonary embolism.
There are multiple absolute and relative indications for
the use of vena cava filters in VTE [19,20] and concomi-
tant therapy with anticoagulation is typically used in
patients with severe cardiopulmonary disease and deep
venous thrombosis [20]. Recent data suggest anticoagula-
tion during and after the insertion of vena cava filter for
patients who have no contraindications [21]. However,
combined therapy with an alternative anticoagulant mer-
its further evaluation, in terms of efficacy, safety, and
duration of therapy.
A possible limitation of the study may be considered the
expression of the ELISA results, as percent of the absorb-
ance measured at 450 nm with a positive control, instead
of using optical density (OD) units. Antibody titers were
estimated high, taking into consideration that they were
almost four and three fold higher than the cut-off value in
both cases. Literature data regarding the association of this
method expression with the relative risk of thrombosis are
lacking, yet it has recently been applied in order to follow
the disappearance of anti-PF4/heparin antibodies under
fondaparinux administration in a patient with HIT [22].
Conclusion
Managing anticoagulation in patients with HIT and mas-
sive pulmonary embolism can be extremely difficult and
challenging. Fondaparinux may be a viable alternative
option, however randomized controlled clinical trials are
needed to establish its use in this group of patients, as well
as its combination with intravascular insertion of IVC fil-
ters for the prevention of embolic events.
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